摘要
目的:探讨经皮肝穿刺门静脉化疗栓塞治疗原发性肝癌门静脉癌栓的临床价值。方法:不能手术的伴门静脉癌栓的原发性肝癌45例,随机分成两组,研究组20例以TACE+PVE治疗,25例以单纯TACE治疗作为对照组,分别统计AFP的变化、门静脉癌栓缩小/消失的有效率以及1年生存率。结果:两组治疗前后AFP的变化:研究组(730±190)、(515±395)μg/L,对照组(752±183)、(710±213)μg/L,治疗后两组比较差异有显著性(P<0.05);两组门静脉癌栓缩小/消失率13/20(65%)、8/25(32%)(P<0.05);1年生存率15/20(75%)、12/25(48%)(P<0.05);两组均未见与治疗相关的严重副作用发生。结论:经皮肝穿刺门静脉化疗栓塞是治疗原发性肝癌门静脉癌栓的有效方法。
Purpose：To assess the therapeutic value of percutaneous portal vein chemoembolizaiton（PVE）for primary hepatic earcinoma（PHC） with portal vein tumor tbrombus.Methods：45 unresectable PHC with portal vein tumor thrombus cases were randomly divided into two groups.The observation group was treated with transcatheter arterial chemoembolization（TACE）＋PVE,while the control group was treated with TACE only.The changes of AFP,response rates of portal vein tumor thrombu and survival rates of one year were analyzed respectively.Results：The levels of AFP before and after treatment were（730±190）μg/L and （515±395）μg/L in the observation group,（752±183）μg/L and （710±213）μg/L in the control group respectively.The difference between the two groups was signifieant（P〈0.05）.The reduetion/disappearance rates of portal vein tumor thrombus were 13/20（65%） and 8/25（32%）（P〈0.05）.The 1-year survival rates were 15/20（75%）and 12/25（48%）（P〈0.04）.There was no severe side-effect related to therapy observed in both two groups.Conclusions：PVE is an effective method in the treatment of PHC with portal vein tumor thrombus.
出处
《中国癌症杂志》
CAS
CSCD
2005年第4期381-382,共2页
China Oncology
关键词
原发性肝癌
门静脉癌栓
化疗栓塞
primary hepatic carcinoma
portal vein tumor thrombus
chemoembolization
